Ftse Mib
32.790,04
0,38%
DAX
18.015,60
-0,03%
S&P 500
5.431,60
0,00%
NASDAQ
17.688,88
0,00%
Bitcoin
65.489,46
-1,73%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ 4D Pharma PLC (LBPS) 4D Pharma PLC (LBPS) Notizie

LBPS

4D Pharma (LBPS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:LBPS
DataOraFonteTitoloSimboloCompagnia
03/01/202318:10Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LBPS4D Pharma PLC
19/07/202217:49Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:LBPS4D Pharma PLC
28/06/202219:50Business Wire4D pharma plc (“4D pharma”) Receives Notice of Delisting From NasdaqNASDAQ:LBPS4D Pharma PLC
27/06/202214:15TipRanksWhat Made Chardan Capital Downgrade 4d Pharma’s Stock?NASDAQ:LBPS4D Pharma PLC
24/06/202221:32TipRanksLadenburg Thalmann & Co. Downgrades 4d Pharma (LBPS) to HoldNASDAQ:LBPS4D Pharma PLC
24/06/202220:41Business WireUpdate on Suspension of TradingNASDAQ:LBPS4D Pharma PLC
26/05/202223:30Business Wire4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:LBPS4D Pharma PLC
19/05/202222:30Business Wire4D pharma to Present at the H.C. Wainwright Global Investment ConferenceNASDAQ:LBPS4D Pharma PLC
17/05/202213:00Business Wire4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International ConferenceNASDAQ:LBPS4D Pharma PLC
29/04/202212:34Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:LBPS4D Pharma PLC
31/03/202223:27Business Wire4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022NASDAQ:LBPS4D Pharma PLC
28/03/202223:29Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3/a)NASDAQ:LBPS4D Pharma PLC
23/03/202212:00Business Wire4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell CarcinomaNASDAQ:LBPS4D Pharma PLC
02/03/202223:26Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:LBPS4D Pharma PLC
28/02/202222:34Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:LBPS4D Pharma PLC
23/02/202213:00Business Wire4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines SummitNASDAQ:LBPS4D Pharma PLC
22/02/202213:00Business Wire4D pharma Announces FDA Clearance of IND Application for Live Biotherapeutics MRx0005 and MRx0029 for the Treatment of Parkinson’s DiseaseNASDAQ:LBPS4D Pharma PLC
18/02/202223:03Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:LBPS4D Pharma PLC
18/02/202223:02Edgar (US Regulatory)Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)NASDAQ:LBPS4D Pharma PLC
28/01/202212:45TipRanksLadenburg Thalmann & Co. Thinks 4d Pharma’s Stock is Going to RecoverNASDAQ:LBPS4D Pharma PLC
27/01/202213:00Business Wire4D pharma Announces Additional Positive Data From Part A of the Phase I/II Trial Of MRx-4DP0004 For the Treatment of AsthmaNASDAQ:LBPS4D Pharma PLC
20/01/202213:00Business Wire4D pharma to Host Virtual KOL Event Discussing Asthma Treatment Landscape and Review of Positive Topline Results from Part A of Phase I/II Trial of MRx-4DP0004NASDAQ:LBPS4D Pharma PLC
20/01/202212:45TipRanksLadenburg Thalmann & Co. Maintains a Buy Rating on 4d Pharma (LBPS)NASDAQ:LBPS4D Pharma PLC
05/01/202213:00Business Wire4D pharma to Present at the H.C. Wainwright BioConnect ConferenceNASDAQ:LBPS4D Pharma PLC
03/01/202213:00Business Wire4D pharma appoints John Doyle as Chief Financial OfficerNASDAQ:LBPS4D Pharma PLC
13/12/202113:00Business Wire4D Pharma Announces Positive Topline Results From Part a of Phase I/II Trial of MRx-4DP0004 for the Treatment of AsthmaNASDAQ:LBPS4D Pharma PLC
09/12/202113:00Business Wire4D pharma Presents Microbiome Analyses from Phase II Clinical Trial of Blautix® for IBS-C and IBS-D at Gastro 2021NASDAQ:LBPS4D Pharma PLC
15/11/202114:00GlobeNewswire Inc.CoImmune, Inc. Appoints Ed Baracchini, PhD, Chairman of the Board of DirectorsNASDAQ:LBPS4D Pharma PLC
11/11/202113:00Business Wire4D pharma to Participate in Jefferies London Healthcare ConferenceNASDAQ:LBPS4D Pharma PLC
12/10/202113:00Business Wire4D pharma to Participate in Jefferies Virtual Next Generation IBD Therapeutics SummitNASDAQ:LBPS4D Pharma PLC
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:LBPS

La tua Cronologia

UNSW3
ZACHETH
ZachXBT
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network